Particle News: Latest Regeneron Pharmaceuticals news

J&J Commits $2 Billion to 10-Year Fujifilm Deal for North Carolina Biologics Hub

The incumbency advances J&J’s $55 billion U.S. manufacturing plan in response to proposed drug‑import tariffs.

Dupixent Fuels Q2 Revenue Gains for Sanofi and Regeneron with Divergent Profit Results

Bankruptcy Court Approves $305 Million Sale of 23andMe to Wojcicki Nonprofit

FDA Approves Regeneron and Sanofi’s Dupixent for Bullous Pemphigoid

Anne Wojcicki Wins 23andMe Auction as UK ICO Fines Company £2.31 Million

Anne Wojcicki’s Nonprofit Wins Bid to Acquire 23andMe for $305 Million

Mixed Phase 3 Outcomes Cloud Future of Regeneron and Sanofi’s COPD Candidate Itepekimab

Regeneron to Acquire 23andMe for $256 Million Following Bankruptcy Auction

FDA Approves Regeneron-Sanofi's Dupixent for COPD Treatment

Diana Taurasi Opens Up About Eczema and Advocates for WNBA Rookies

Pioneering Gene Therapy Restores Hearing in Deaf Toddler

Sanofi and Regeneron's Dupixent Shows Promising Results in Second COPD Trial